Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15580406 | 0.67 | — | — | |
| SCHEMBL2843814 | 0.66 | — | — | |
| Hydrochloric Acid SCHEMBL34474173 | 0.64 | OPRM1 (0.31) | OPRM1OPRK1OPRL1 | |
| SCHEMBL10355690 | 0.62 | — | — | |
| SCHEMBL34473917 | 0.62 | — | — | |
| SCHEMBL30807876 | 0.62 | — | — | |
| SCHEMBL21798157 | 0.60 | — | — | |
| Hydrochloric Acid SCHEMBL20502526 | 0.60 | — | — | |
| SCHEMBL18583709 | 0.60 | SLC6A4 (0.35) | OPRM1OPRK1OPRL1 | |
| SCHEMBL7603960 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
| EP-3668601-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2020-06-24 | — | — | EP | disclosed |
| CN-111107903-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019034696-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034696-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773058-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, NLRP1 | OPRM1 1263/4885OPRK1 1369/4885OPRL1 242/4885 |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | OPRM1 972/4885OPRK1 1233/4885OPRL1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.